European equities closed sharply lower on Thursday, as a raft of weak earnings offset positive sentiment surrounding the rebound in oil prices.
Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.
Goldman's Robert Boroujerdi presented seven future theme predictions and their investment implications in a note to clients Wednesday.
European equities closed the session mixed Wednesday as investors digested inflation numbers and contemplated the possibility of further stimulus.
An FDA rule created to spur drug companies to develop treatments for rare diseases is being used far beyond its original scope, critics say.
European equities closed sharply lower on Friday as slumping commodity prices and weak earnings reports weighed on investor sentiment.
Norway's sovereign wealth fund, the largest in the world by assets, reported a loss in the third quarter of this year as the global sell-off in risk assets hit the fund's equity holdings.
European markets jumped higher on Thursday, after the European Central Bank's president said that policy would be re-examined in December.
Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.
DAX all folks
European stocks ended lower on Thursday, after a flurry of corporate earnings came out from across the region.
Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.
Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.
European equities closed mixed on Monday as investors reacted to new economic data and cheered updates from the pharmaceutical sector.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.
European shares finished mixed on Wednesday, as investors digested a slew of earnings from European companies.
Roche, the world's biggest maker of cancer drugs, reported a 3 percent rise in sales in the first quarter on Wednesday.